HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma

WBC Stevens; Katerina Bakunina; M Cuijpers; M Chamuleau; A Beeker; R Fijnheer; H Hebart; HPJ Visser; Jeanette Doorduijn; K Linton; M Dreyling; D Jong; MJ Kersten

doi:10.1097/hs9.0000000000000325

HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma

WBC Stevens, Katerina Bakunina, M Cuijpers, M Chamuleau, A Beeker, R Fijnheer, H Hebart, HPJ Visser, Jeanette Doorduijn, K Linton, M Dreyling, D Jong, MJ Kersten

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

26 Downloads (Pure)

Original language	English
Article number	e325
Journal	HemaSphere
Volume	4
Issue number	1
DOIs	https://doi.org/10.1097/hs9.0000000000000325
Publication status	Published - 2020

Research programs

EMC OR-01

Access to Document

10.1097/hs9.0000000000000325

Repub_128616_O-A.pdfFinal published version, 236 KB

Cite this

Stevens, WBC., Bakunina, K., Cuijpers, M., Chamuleau, M., Beeker, A., Fijnheer, R., Hebart, H., Visser, HPJ., Doorduijn, J., Linton, K., Dreyling, M., Jong, D., & Kersten, MJ. (2020). HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma. HemaSphere, 4(1), Article e325. https://doi.org/10.1097/hs9.0000000000000325

@article{c1d5734066fc4923b636f2eee50da98e,

title = "HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma",

author = "WBC Stevens and Katerina Bakunina and M Cuijpers and M Chamuleau and A Beeker and R Fijnheer and H Hebart and HPJ Visser and Jeanette Doorduijn and K Linton and M Dreyling and D Jong and MJ Kersten",

year = "2020",

doi = "10.1097/hs9.0000000000000325",

language = "English",

volume = "4",

journal = "HemaSphere",

issn = "2572-9241",

publisher = "Wolters Kluwer Health (U.S.)",

number = "1",

}

Stevens, WBC, Bakunina, K, Cuijpers, M, Chamuleau, M, Beeker, A, Fijnheer, R, Hebart, H, Visser, HPJ, Doorduijn, J, Linton, K, Dreyling, M, Jong, D & Kersten, MJ 2020, 'HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma', HemaSphere, vol. 4, no. 1, e325. https://doi.org/10.1097/hs9.0000000000000325

HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma. / Stevens, WBC; Bakunina, Katerina; Cuijpers, M et al.
In: HemaSphere, Vol. 4, No. 1, e325, 2020.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma

AU - Stevens, WBC

AU - Bakunina, Katerina

AU - Cuijpers, M

AU - Chamuleau, M

AU - Beeker, A

AU - Fijnheer, R

AU - Hebart, H

AU - Visser, HPJ

AU - Doorduijn, Jeanette

AU - Linton, K

AU - Dreyling, M

AU - Jong, D

AU - Kersten, MJ

PY - 2020

Y1 - 2020

U2 - 10.1097/hs9.0000000000000325

DO - 10.1097/hs9.0000000000000325

M3 - Article

SN - 2572-9241

VL - 4

JO - HemaSphere

JF - HemaSphere

IS - 1

M1 - e325

ER -